Fig. 2.

The cisplatin sensitivity signature that was generated from IRAPS predicts cisplatin-treated ovarian cancer patient survival independent of cancer stage and grade. a ROC curve based on the cisplatin sensitivity score using the cisplatin testing set that consisted of triple-negative breast cancer and ovarian cancer cell lines. b ROC curve for the same cells as in 2a, but based on the BRCAness sensitivity signature score. c, d Patient survival analyses in two independent cohorts of ovarian cancer patients that were treated with cisplatin were separated based on the cisplatin sensitivity score. Log-rank p-value is displayed that shows statistical significance. e, f High cisplatin sensitivity scores predict improved overall survival (e) and progression free survival (f) independent of stage and grade using a Cox proportional hazards model. g Ingenuity pathway analysis of the cisplatin sensitivity signature indicates a predicted down-regulation of BRCA1